

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21

Potential risk polarization for acute myocardial infarction during the COVID-19 pandemic: Single-center experiences in Osaka, Japan

Masato Furui^{1,2*}, Kenji Kawajiri³, Takeshi Yoshida², Bunpachi Kakii², Norikazu Oshiro², Mai Asanuma², Hiroaki Nishioka⁴, Hideichi Wada¹

¹ Cardiovascular Surgery Department, Fukuoka University Hospital, Nanakuma, Fukuoka, Fukuoka, Japan

² Cardiovascular Surgery Department, Matsubara Tokushukai Hospital, Amamihigashi, Matsubara, Osaka, Japan

³ Cardiology Department, Matsubara Tokushukai Hospital, Amamihigashi, Matsubara, Osaka, Japan

⁴ Surgery Department, Matsubara Tokushukai Hospital, Amamihigashi, Matsubara, Osaka, Japan

Short title: Acute myocardial infarction after the COVID-19 pandemic
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

22

23 * Corresponding author:

24 E-mail: masatofurui@yahoo.co.jp (MF)

25

26 **Abstract**

27 This study compared the time course and outcomes of acute myocardial infarction,
28 including mechanical complications and hospital mortality, before and after the coronavirus
29 disease 2019 (COVID-19) pandemic at a regional core hospital in South Osaka, Japan.
30 Moreover, it identified predictors for hospital mortality and mechanical complications. In total,
31 503 patients who underwent emergency percutaneous coronary intervention between January
32 2011 and December 2021 at our institution were examined retrospectively. The time course of
33 acute myocardial infarction, mechanical complications, and mortality rate before and after the
34 COVID-19 emergency declaration were compared. Overall, 426 patients with ST-segment
35 elevation myocardial infarction and 77 patients with non-ST-segment elevation myocardial
36 infarction were identified. For patients with ST-segment elevation myocardial infarction, the
37 onset-to-door time was longer (181 vs. 156 min, $P = 0.001$) and mechanical complications
38 were worse (7.8% vs. 2.6%, $P = 0.025$) after the emergency declaration of COVID-19 than
39 before the pandemic. Age, low ejection fraction, out-of-hospital cardiac arrest, and mechanical
40 complications were identified as independent risk factors for hospital mortality among patients
41 with ST-segment elevation myocardial infarction, using multivariable analysis.
42 Post-declaration, age, walk-ins, referrals, and intra-aortic balloon pump use were independent
43 predictors of mechanical complications among patients with ST-segment elevation myocardial
44 infarction. Onset-to-door time and mechanical complication rate increased after the COVID-19
45 declaration among patients with ST-segment elevation myocardial infarction. Arrival by
46 walk-in and a referral that caused treatment delay were identified as independent risk factors
47 for mechanical complication, in addition to age, use of intra-aortic balloon pump, and
48 post-declaration of COVID-19. Therefore, the risks posed by the COVID-19 pandemic might
49 have a polarization tendency resulting from the relief or worsening of cardiac symptoms.

51 **Introduction**

52 The coronavirus disease 2019 (COVID-19) pandemic has been in existence since
53 2020. The infection situation is not much different in Japan, and the nation has already
54 experienced the sixth wave of COVID-19. Common behavioral patterns have been adjusted to
55 reduce infection risk, and patients are being asked to avoid population-dense areas for the same
56 reason. Accordingly, a reduction in hospitalizations for acute myocardial infarction (AMI) has
57 been reported. [1–6] Although the impact of the COVID-19 pandemic on door-to-balloon time
58 and mechanical complications of AMI have been previously examined in other countries, such
59 reports are still scarce in Japan. [7–10]

60 A few studies on percutaneous coronary intervention (PCI) impact in Tokyo, Japan,
61 have been reported; however, whether these are relevant to other regions is unknown due to the
62 rural-urban emergency care disparity. [11,12] For example, South Osaka does not include a
63 metropolitan area, being the second largest prefecture in Japan; therefore, accessibility to
64 PCI-capable institutions will be different from that in Tokyo. [13,14] After the pandemic,
65 studies considering consultation forms, such as walk-ins, direct arrival by emergency medical
66 service (EMS), or referral transport from other non-PCI-capable facilities, are rare. [14]

67 Therefore, this study compared the time course and outcomes of AMI, including
68 mechanical complications and in-hospital mortality, before and after the COVID-19 pandemic
69 declaration at a regional core hospital in South Osaka, Japan. Moreover, this study examined
70 whether differences in types of hospital visits were a predictor of the outcomes.

71

72 **Materials and Methods**

73 **Study design and population**

74 The study protocol conformed to the ethical guidelines of the Declaration of Helsinki
75 and was approved by the Ethics Committee of the Matsubara Tokushukai Hospital (approval
76 number: 22-01). The informed consent requirement from patients was waived due to the
77 retrospective nature of this study. The corresponding author (Masato Furui) has full access to
78 all data in this study and takes responsibility for data integrity and analysis.

79 This study was a retrospective observational cohort study conducted on patients who
80 underwent emergency PCI for AMI at the Matsubara Tokushukai Hospital in Osaka, Japan,
81 between January 2011 and December 2021. The medical records of 796 patients with acute
82 coronary syndrome (ACS) were reviewed, and data of 503 AMI patients were extracted after
83 excluding those with recent myocardial infarction (MI) with an onset-to-door time >14 days
84 and unstable angina pectoris. The participants were classified into ST-segment elevation
85 myocardial infarction (STEMI) and non-STEMI (NSTEMI) groups. The Japanese government
86 declared a state of emergency on April 7, 2020, following the World Health Organization's
87 initial declaration of COVID-19 as a pandemic on March 11, 2020. [15,16] With this
88 emergency declaration as a borderline, the characteristics, time course, and outcomes were
89 compared before and after the declaration to evaluate the impact of the COVID-19 pandemic
90 on both the STEMI and NSTEMI groups (Figure 1).

91

92 **Fig 1. Flow chart illustrating the selection of the study participants.** Abbreviations: ACS,
93 acute coronary syndrome; AMI, acute myocardial infarction; MI, myocardial infarction;
94 NSTEMI, non-ST-segment elevation myocardial infarction; STEMI, ST-segment elevation
95 myocardial infarction; UAP, unstable angina pectoris.

96

97 **Definitions**

98 AMI was defined based on the fourth universal definition of MI, and ACS was defined
99 according to the Japanese Circulation Society guidelines. [17,18] Infarction was classified into
100 STEMI or NSTEMI, depending on the presence or absence of ST-segment elevation.
101 Onset-to-door time and door-to-balloon time were defined as the time from symptom onset to
102 hospital arrival and from hospital arrival to balloon dilation or thrombus aspiration,
103 respectively. [19] In the present study, renal dysfunction was defined as creatinine level >1.5
104 mg/dL. Left ventricular ejection fraction (LVEF) was assessed using echocardiography.
105 Primary PCI was defined as urgent balloon angioplasty (with or without stenting) without
106 employing fibrinolytic therapy to open the infarct-related artery.

107 The primary outcomes were onset-to-balloon time and in-hospital mortality. The
108 secondary outcome was the incidence of mechanical complications. Therefore, we compared
109 onset-to-door time, mechanical complications, and hospital mortality between patients before
110 and after the COVID-19 emergency declaration in Japan. Mechanical complications, including
111 cardiac rupture, ventricular septal perforation, and papillary muscle rupture, were assessed
112 using echocardiography. [20–22]

113

114 **Statistical analysis**

115 Categorical variables were expressed as numbers and proportions, whereas
116 continuous variables were presented as mean±standard deviation. Student's t-test, chi-squared
117 test, and Mann–Whitney U test were utilized for other statistical analyses. Multivariate logistic
118 regression analysis was performed for risk factors associated with hospital mortality and

119 mechanical complications in patients with STEMI. This analysis considered age, walk-ins,
120 referrals, out-of-hospital cardiac arrest (OHCA), LVEF, single-vessel disease, anterior MI as a
121 culprit, onset-to-door time, intra-aortic balloon pump (IABP) use, mechanical complications,
122 and post-COVID-19 declaration, as possible predictors. [7,22,23] The odds ratios (OR) and
123 95% confidence intervals (CI) were calculated. The number of patients who underwent
124 venoarterial extracorporeal membrane oxygenation was few; therefore, it was not entered
125 because we could not effectively analyze it. Moreover, NSTEMI analysis was not valid due to
126 the small number. All statistical analyses were performed using JMP® version 9.0 (SAS
127 Institute Inc., Cary, NC), and differences were considered statistically significant at a *P*-value
128 <0.05.

129

130 **Results**

131 We extracted the data of 796 patients who required emergency PCI for ACS from
132 medical records. Of these, 503 AMI patients were identified as participants in this study
133 (Figure 1), of whom 426 and 77 patients were categorized into the STEMI and NSTEMI
134 groups, respectively. Table 1 summarizes the basic characteristics, including the patients'
135 background and pre-PCI examination findings before and after the COVID-19 declaration in
136 each group. In the STEMI group, the number of patients with Killip classes III–IV was
137 significantly higher after the declaration than it was before the declaration (12.0% [42/349] vs.
138 21.3% [16/77], *P*=0.010). Although the prevalence of OHCA was not significantly different, it
139 tended to be higher after the declaration (2.3% [8/349] vs. 6.5% [5/77], *P*=0.052). There were
140 no significant differences in comorbidities, clinical presentation, and laboratory data before
141 and after the declaration, except for Killip III–IV classification in the STEMI group, as

142 previously described.

143

144 **Table 1. Basic characteristics of AMI patients before and after the COVID-19**
145 **declaration.**

Demographic s n (%) or mean±SD	STEMI (n=426)			NSTEMI (n=77)		
	Before declaration (n=349)	After declaration (n=77)	<i>P</i> -value	Before declaration (n=62)	After declaration (n=15)	<i>P</i> -value
Age (year)	67.7±12.6	68.7±11.9	0.514	67.3±12.7	71.6±11.4	0.152
Sex (male)	268 (76.8%)	55 (71.4%)	0.139	46 (74.2%)	7 (46.7%)	0.842
Body mass index (kg/m ²)	24.0±4.0	23.7±4.0	0.642	23.7±3.9	22.3±3.5	0.703
<i>Comorbidities</i>						
Hypertension	189 (54.2%)	45 (58.4%)	0.494	35 (56.5%)	8 (53.3%)	0.075
Diabetes mellitus	100 (28.7%)	24 (31.2%)	0.660	15 (24.2%)	3 (20.0%)	0.737
Dyslipidemia	121 (34.7%)	30 (39.5%)	0.428	20 (32.3%)	7 (46.7%)	0.063
Renal dysfunction	161 (46.1%)	27 (35.0%)	0.077	25 (40.3%)	3 (20.0%)	0.277
Dialysis	4 (1.1%)	2 (2.6%)	0.328	1 (1.6%)	0 (0%)	0.621

Cerebral infarction	22 (6.3%)	5 (6.5%)	0.951	5 (8.1%)	3 (20.0%)	0.102
COPD	3 (0.9%)	0 (0%)	0.414	0 (0%)	10 (66.7%)	0.041*
Prior PCI	36 (10.3%)	7 (9.1%)	0.747	9 (14.5%)	2 (13.3%)	0.187
<i>Clinical presentation</i>						
Killip classification [†]	307 (88.0%)	59 (78.7%)	0.010*	58 (93.5%)	10 (100%)	0.312
I – II						
III–IV	42 (12.0%)	16 (21.3%)		4 (6.5%)	0 (0%)	
OHCA	8 (2.3%)	5 (6.5%)	0.052	1 (1.6%)	1 (6.7%)	0.270
LVEF (%)	47±12	47±13	0.618	48±14	50±15	0.374
<i>Laboratory data</i>						
CPK [‡] (U/L)	453±771	398±622	0.562	529±881	255±234	0.256
Peak CPK (U/L)	3198±2808	3428±3038	0.528	2073±2380	799±730	0.156
CK-MB [‡] (U/L)	49±84	39±52	0.377	69±122	30±34	0.262
Peak CK-MB (U/L)	297±302	274±216	0.531	189±199	80±75	0.248
Troponin I [‡] (pg/mL)	9378±3696	5491±1882	0.406	7905±2859	5855±1041	0.702
	1	1		0		

146 AMI, acute myocardial infarction; CK, creatine kinase-myocardial band; CPK, creatine
 147 phosphokinase; LVEF, left ventricular ejection fraction; OHCA, out-of-hospital cardiac arrest;

148 PCI, percutaneous coronary intervention; and SD, standard deviation.

149 * $P < 0.05$.

150 †Killip classification after the declaration has a defect value of 2 in STEMI and 5 in NSTEMI.

151 ‡Value at admission.

152

153 Table 2 shows consultation types, (such as walk-ins, arrival by EMS, and referrals,) the time course, and outcomes before and after the declaration in each group. In the STEMI group, there were fewer referred patients after the declaration than there were before the declaration. However, there was no significant difference in the door-to-balloon time before and after the declaration (109±129 vs. 96±54 min, $P=0.420$). Onset-to-door time (a primary outcome) in patients with STEMI was significantly longer after the COVID-19 declaration than it was before the declaration (156±134 vs. 181±145 min, $P=0.001$).

160

161 **Table 2. Consultation type, time course, and outcomes in AMI patients before and after**
 162 **the declaration.**

Demographics			STEMI (n=426)			NSTEMI (n=77)		
n	(%)	or	Before	After	<i>P</i> -value	Before	After	<i>P</i> -value
mean±SD			declaratio	declaratio	e	declaratio	declaratio	e
			n	n		n	n	
			(n=349)	(n=77)		(n=62)	(n=15)	
<i>Consultation</i>								
<i>type</i>								

Walk-in	50 (14.3%)	12 (16.0%)	0.733	9 (14.5%)	3 (20%)	0.599
EMS	296 (85.3%)	64 (83.1%)	0.710	52 (83.9%)	12 (80.0%)	0.720
In-hospital patients	2 (0.6%)	1 (1.3%)	0.491	1 (1.6%)	0 (0%)	0.621
Referral	94 (27.0%)	11 (14.3%)	0.019*	19 (30.7%)	2 (13.3%)	0.177
<i>Time course</i>						
Onset-to-door (min)	156±134	181±145	0.001*	126±134	186±158	0.327
Door-to-balloon n (min)	109±129	96±54	0.420	120±60	117±54	0.609
<i>Culprit</i>						
LMT	6 (1.7%)	1 (1.3%)	0.785	6 (9.7%)	0 (0%)	0.096
LAD	160 (45.9%)	34 (44.2%)		19 (30.7%)	6 (40%)	
LCX	34 (9.7%)	9 (11.7%)		16 (25.8%)	8 (53.3%)	
RCA	148 (42.4%)	32 (41.6%)		19 (30.7%)	1 (6.7%)	
Diagonal branch	1 (0.3%)	1 (1.3%)		2 (3.2%)	0 (0%)	
<i>Mechanical</i>						
<i>Circulatory</i>						
<i>Support</i>						
IABP	22 (6.3%)	7 (9.1%)	0.383	7 (11.3%)	0 (0%)	0.172

VA-ECMO	11 (3.2%)	4 (5.2%)	0.382	2 (3.2%)	0 (0%)	0.481
<i>Outcomes</i>						
Mechanical complications	9 (2.6%)	6 (7.8%)	0.025*	1 (1.6%)	1 (6.7%)	0.270
Cardiac rupture	6 (1.7%)	3 (4.0%)	0.231	1 (1.6%)	0 (0%)	0.621
Ventricular septal perforation	2 (0.6%)	2 (2.7%)	0.100	0 (0%)	0 (0%)	-†
Papillary muscle rupture	1 (0.3%)	1 (1.3%)	0.241	0 (0%)	1 (6.7%)	0.041*
In-hospital mortality	36 (10.3%)	11 (14.3%)	0.299	5 (8.1%)	1 (6.7%)	0.856

163 EMS, emergency medical service; IABP, intra-aortic balloon pump; LAD, left anterior
 164 descending coronary artery; LCX, left circumflex coronary artery; LMT, left main trunk;
 165 NSTEMI, non-ST-segment elevation myocardial infarction; RCA, right coronary artery; SD,
 166 standard deviation; STEMI, ST-segment elevation myocardial infarction; and VA-ECMO,
 167 venoarterial extracorporeal membrane oxygenation.

168 * $P < 0.05$.

169 †The value is not valid.

170

171 Hospital mortality, another primary outcome, occurred in 11.0% (47/426) of patients
 172 with STEMI and 7.8% (6/77) of patients with NSTEMI. Contrarily, mechanical complications,
 173 a secondary outcome, occurred in 3.5% (15/426) of patients with STEMI patients and 2.6%

174 (2/77) of patients with NSTEMI. The mechanical complication rate was significantly higher
175 after the COVID-19 declaration than it was before the declaration (2.6% [9/349] vs. 7.8%
176 [6/77], $P=0.025$) in the STEMI group; however, there was no significant difference in hospital
177 mortality (10.3% [36/349] vs. 14.3% [11/77], $P=0.299$).

178 Table 3 presents the results of the multivariate analysis for the primary outcomes. Age
179 (1-year increase: OR 1.087, 95% CI 1.045–1.135, $P \leq 0.0001$), OHCA (OR 61.883, 95% CI
180 9.726–595.506, $P<0.0001$), LVEF (1% increase: OR 0.943, 95% CI 0.911–0.975, $P=0.0004$),
181 IABP use (OR 10.523, 95% CI 3.544–33.544, $P \leq 0.0001$), and mechanical complications (OR
182 10.724, 95% CI 2.233–57.236, $P=0.003$) were established as independent predictors of
183 hospital mortality. Table 4 presents the results of the multivariate analysis for the secondary
184 outcome. Age (1-year increase: OR 1.115, 95% CI 1.037–1.221, $P=0.0019$), walk-in visits (OR
185 14.695, 95% CI 3.265–80.468, $P=0.0005$), referral visits (OR 4.854, 95% CI 1.050–25.003,
186 $P=0.043$), IABP use (OR 29.094, 95% CI 4.209–255.552, $P=0.0008$), and post-COVID-19
187 declaration (OR 5.006, 95% CI 1.131–22.443, $P=0.035$) were identified as independent
188 predictors of mechanical complications.

189

190 **Table 3. Multivariate logistic regression analysis of risk factors for STEMI.**

Dependent variable: hospital mortality			
	Odds ratio	95% CI	P-value
Age (per year)	1.087	1.045–1.135	<0.0001*
Walk-in	2.000	0.527–10.829	0.332

Referral	0.744	0.289–1.999	0.550
OHCA	61.883	9.726–595.506	<0.0004*
LVEF (1% increase)	0.943	0.911–0.975	0.0019*
Single-vessel disease	1.009	0.420–2.418	0.9845
Culprit: anterior (vs. others)	1.584	0.661–3.929	0.3042
Onset-to-door time (per min)	1.001	0.998–1.005	0.5175
IABP	10.523	3.544–33.544	<0.0001*
Mechanical complications	10.724	2.233–57.236	0.0030*
Post-declaration pre-declaration)	(vs. 1.030	0.293–3.129	0.9603

191 CI, confidence interval; IABP, intra-aortic balloon pump; LVEF: left ventricular ejection
 192 fraction; OHCA, out-of-hospital cardiac arrest; and STEMI, ST-segment elevation myocardial
 193 infarction.

194 * $P < 0.05$.

195

196 **Table 4. Multivariate logistic regression analysis of risk factors for STEMI.**

Dependent variable: mechanical complications			
	Odds ratio	95% CI	P-value
Age (per year)	1.115	1.037–1.221	0.0019*
Walk-in	14.695	3.265–80.468	0.0005*
Referral	4.854	1.050–25.003	0.0432*

LVEF (1% increase)	0.971	0.915–1.030	0.276
Single-vessel disease	2.478	0.619–11.348	0.202
Culprit: anterior (vs. others)	3.330	0.792–16.673	0.102
Onset-to-door time (per min)	1.003	0.999–1.006	0.085
IABP	29.094	4.209–255.552	0.0008*
Post-declaration (vs. pre-declaration)	5.006	1.131–22.443	0.035*

197 CI, confidence interval; IABP, intra-aortic balloon pump; LVEF, left ventricular ejection
 198 fraction; and STEMI, ST-segment elevation myocardial infarction.

199 * $P < 0.05$.

200

201 Table 5 shows the association of walk-ins and referrals with the time course after the
 202 declaration in patients with STEMI. Regarding arrival by walk-in, both onset-to-door and
 203 door-to-balloon times were significantly extended in patients with walk-in arrivals, compared
 204 with those from non-walk-in arrivals (175 vs. 127 min, $P = 0.015$ and 150 vs. 95 min, $P = 0.038$).
 205 Conversely, referral patients had a significantly longer onset-to-door time (164 vs. 124 min,
 206 $P = 0.016$) and shorter door-to-balloon time than non-referral patients (87 vs. 113 min,
 207 $P = 0.009$).

208

209 **Table 5. The association of walk-ins and referrals with time course after COVID-19**
 210 **declaration in the STEMI group.**

Time course	Walk-in	Non-walk-in	<i>P</i> -value	Referral	Non-referral	<i>P</i> -value
mean (range)	(n=65)	(n=31)		(n=105)	(n=321)	

Onset-to-door time (min)	175 840)	(12– 127 (6–1080)	0.015*	164 1080)	(6– 124 (6–840)	0.016*
Door-to-balloon time (min)	150 1337)	(42– 95 (29–437)	0.038*	87 199)	(29– 113 (38– 1337)	0.009*

211 STEMI indicates ST-segment elevation myocardial infarction.

212 * $P < 0.05$.

213

214 Discussion

215 Several studies have reported the impact of the COVID-19 pandemic on AMI in
 216 Tokyo. [3,7] However, our hospital’s secondary medical service area in South Osaka is distinct
 217 from that in Tokyo and has an unevenly distributed population, similar to hospitals, especially
 218 PCI-capable facilities. [13,24,25] Moreover, arrival by walk-in or referral as risk factors for
 219 AMI have rarely been discussed following the COVID-19 pandemic. Therefore, our study
 220 investigated the influence of walk-ins and referrals on mechanical complications and hospital
 221 mortality to address this and compare time course and outcomes before and after the
 222 COVID-19 pandemic in STEMI and NSTEMI groups. We established that onset-to-door time
 223 was prolonged and mechanical complications developed more frequently in STEMI patients
 224 after the COVID-19 declaration, with no significant difference between both groups. These
 225 findings suggest that, in addition to post-COVID-19 declaration, walk-ins and referrals were
 226 risk factors for mechanical complications.

227 Regarding risk factors for hospital mortality, it was reported that patients with lower
 228 LVEF have higher mortality rates and develop heart failure easily. [26,27] Once mechanical
 229 complications occur, they can fatally affect patients’ hemodynamics. Although various

230 operative procedures and strategies in surgery timing have been devised, operative mortality
231 remains high. [21,22,28] Therefore, investigating the risk factors and preventing subsequent
232 complications may be important in reducing associated mortality.

233 Several risk factors for mechanical complications are known; previous studies have
234 shown that established mechanical complication risk factors include age, female sex, anterior
235 MI, de novo MI, and single-vessel disease. However, the analysis conducted in this study did
236 not identify single-vessel disease and anterior MI as mechanical complication risk factors.
237 [21,22] Moreover, once mechanical complications occur, patients often experience cardiogenic
238 shock, thus requiring IABP use, which may naturally become a risk factor.

239 Considering previous findings, the identification of walk-ins and referrals as risk
240 factors for mechanical complications are unique points in the present study. Walk-in patients
241 often have mild symptoms, making this seem contradictory. However, in some cases with mild
242 symptom presentation, patients' hearts can suffer from unnoticed load until AMI diagnosis,
243 even after visiting the hospital because of unrestricted patient mobility or activity. Failure to
244 limit this activity may become a mechanical complication risk. Thus, the time course for
245 walk-in patients is distinct from that for patients transported by ambulance. Patients who notify
246 the EMS are likely to immediately undergo consultation and check-ups by emergency doctors
247 who begin monitoring as soon as the patient arrives at the hospital. Useful information by
248 rescue crews generally aids in smooth AMI diagnosis. Conversely, walk-in patients have to
249 wait longer for consultation or check-ups. Therefore, there may be a pronounced time lag from
250 their arrival to diagnosis or PCI, compared with that of patients who notify EMS.

251 Referred patients were reported to have a prolonged onset-to-door time because they
252 came from a nearby clinic or were transferred from non-PCI-capable facilities. [14,19]
253 Previous studies reported that the time interval from an AMI onset to ventricular septal

254 perforation manifestation had a bimodal distribution; therefore, a longer ischemic time can
255 become a risk factor for mechanical complications due to interactions with unknown factors.
256 [10,22] In contrast, there was a significantly shorter door-to-balloon time in referred patients
257 with STEMI after the pandemic declaration. Although we could not specify the reason,
258 preparing for PCI in advance by referral request and an improved acceptance system by the
259 regional cooperation office might achieve a shorter door-to-balloon time. In any case, because
260 a referral is indispensable due to the surrounding non-PCI-capable facilities, we suggest that an
261 effective EMS system and crew education on carrying suspected patients to PCI-capable
262 facilities is important. [11,13,14]

263 In the STEMI group, OHCA rates tended to be higher after the declaration than it was
264 before, although this failed to reach statistical significance. Given the potential for a higher
265 OHCA rate and risk factors for mechanical complications, such as walk-ins and referrals, AMI
266 risk polarization may have emerged on the clinical scene during the COVID-19 pandemic.
267 Although rare, spontaneous reperfusion occurs in 7–30% of patients with STEMI, as stated in
268 previous studies. [29,30] In addition, patients who follow stay-at-home orders and initially
269 tolerate or adapt to their symptoms may likely experience spontaneous reperfusion. Walk-in
270 patients with apparently mild symptoms or referred patients with STEMI may be at risk of
271 mechanical complications, which were identified in the present study as mortality risk in
272 STEMI after the COVID-19 pandemic. Therefore, care should be taken regarding walk-in or
273 referral patients suspected of STEMI.

274 Conversely, more severe symptoms can result in patients notifying EMS; however,
275 their situation can become critical due to delays that may lead to OHCA during transport to
276 PCI-capable facilities. The fear of contracting COVID-19 may have led to patient hesitation to
277 visit hospitals, resulting in risk polarization (Figure 2). Timely arrival to PCI-capable facilities

278 without hesitation is necessary for patients at risk of AMI.

279

280 **Fig 2. Polarization tendency of potential risks occurring from the patients' psychology**
281 **and possible time course after the COVID-19 pandemic.** Abbreviations: EMS, emergency
282 medical service; OHCA, out-of-hospital cardiac arrest.

283

284 The first limitation of this study is its retrospective observational design coupled with
285 limited sample size from a single center. Our hospital covers only one of the areas in South
286 Osaka. Thus, our data may not accurately represent Osaka as a whole because of emergency
287 care or PCI volume disparity. [11–13] Second, additional data, encompassing EMS calls,
288 transfer-to-door time, or COVID-19 examination waiting time, may be desirable in future
289 studies to support the initial findings outlined in this study. Finally, the number of patients who
290 died at home or during transport to our hospital was unknown and were excluded from the
291 study population; therefore, OHCA and AMI prevalence rates may have been underestimated.
292 Future research including these data will be required to further evaluate AMI-related mortality
293 risk or mechanical complications during the COVID-19 pandemic.

294

295 **Conclusion**

296 The onset-to-door time was prolonged and mechanical complications developed more
297 frequently in patients with STEMI after the COVID-19 pandemic declaration than it did
298 before. Age, low LVEF, OHCA, IABP use, and mechanical complications were established as
299 independent risk factors for hospital mortality in patients with STEMI. Additionally, age,

300 walk-ins, referrals, and IABP use were identified as independent predictors of mechanical
301 complications in those with STEMI. Arrival by walk-in or referral, in patients with mild
302 symptoms, influenced the outcomes of patients with AMI. Therefore, the risks posed by the
303 COVID-19 pandemic might have a polarization tendency resulting from the relief or
304 worsening of cardiac symptoms.

305

306 **Acknowledgments**

307 We would like to thank Editage for English editing services.

308

309 **References**

- 310 1. Bhatt AS, Moscone A, McElrath EE, Varshney AS, Claggett BL, Bhatt DL, et al.
311 Fewer hospitalizations for acute cardiovascular conditions during the COVID-19
312 pandemic. *J Am Coll Cardiol*. 2020; 76: 280-288.
- 313 2. Toscano O, Cosentino N, Campodonico J, Bartorelli AL, Marenzi G. Acute myocardial
314 infarction during the COVID-19 pandemic: an update on clinical characteristics and
315 outcomes. *Front Cardiovasc Med*. 2021; 8: 648290.
- 316 3. Arai R, Fukamachi D, Ebuchi Y, Migita S, Morikawa T, Monden M, et al. Impact of
317 the COVID-19 outbreak on hospitalizations and outcomes in patients with acute
318 myocardial infarction in a Japanese single center. *Heart Vessels*. 2021; 36: 1474-1483.
- 319 4. Morishita T, Takada D, Shin JH, Higuchi T, Kunisawa S, Imanaka Y. Trends, treatment
320 approaches, and in-hospital mortality for acute coronary syndrome in Japan during the
321 coronavirus disease 2019 pandemic. *J Atheroscler Thromb*. 2022; 29: 597-607.

- 322 5. De Rosa S, Spaccarotella C, Basso C, Calabrò MP, Curcio A, Filardi PP, et al.
323 Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19
324 era. *Eur Heart J*. 2020; 41: 2083-2088.
- 325 6. Erol MK, Kayıkçıoğlu M, Kılıçkap M, Güler A, Yıldırım A, Kahraman F, et al.
326 Treatment delays and in-hospital outcomes in acute myocardial infarction during the
327 COVID-19 pandemic: a nationwide study. *Anatol J Cardiol*. 2020; 24: 334-342.
- 328 7. Watanabe Y, Miyachi H, Mozawa K, Yamada K, Oka E, Shiomura R, et al. Impact of
329 the COVID-19 pandemic on ST-elevation myocardial infarction from a single-center
330 experience in Tokyo. *Intern Med*. 2021; 60: 3693-3700.
- 331 8. Kitahara S, Fujino M, Honda S, Asaumi Y, Kataoka Y, Otsuka F, et al. COVID-19
332 pandemic is associated with mechanical complications in patients with ST-elevation
333 myocardial infarction. *Open Heart*. 2021; 8: e001497.
- 334 9. Kobayashi S, Sakakura K, Jinnouchi H, Taniguchi Y, Tsukui T, Watanabe Y, et al.
335 Comparison of door-to-balloon time and in-hospital outcomes in patients with
336 ST-elevation myocardial infarction between before versus after COVID-19
337 pandemic. *Cardiovasc Interv Ther*. 2022; 37: 641-650.
- 338 10. Fardman A, Zahger D, Orvin K, Oren D, Kofman N, Mohsen J, et al. Acute myocardial
339 infarction in the Covid-19 era: Incidence, clinical characteristics and in-hospital
340 outcomes- A multicenter registry. *PLoS ONE* 2021; 16: e0253524
- 341 11. Masuda J, Kishi M, Kumagai N, Yamazaki T, Sakata K, Higuma T, et al. Rural-urban
342 disparity in emergency care for acute myocardial infarction in Japan. *Circ J*. 2018; 82:
343 1666-1674.
- 344 12. Matsuzawa Y, Konishi M, Nakai M, Saigusa Y, Taguri M, Gohbara M, et al.

- 345 In-hospital mortality in acute myocardial infarction according to population density
346 and primary angioplasty procedures volume. *Circ J.* 2020; 84: 1140-1146.
- 347 13. Kinoshita N, Imai K, Kinjo K, Naka M. Longitudinal study of acute myocardial
348 infarction in the southeast Osaka district from 1988 to 2002. *Circ J.* 2005; 69:
349 1170-1175.
- 350 14. Higuma T, Hanada H, Okumura K. Direct transfer, shorter onset-to-balloon time, and
351 better clinical outcome in ST-segment elevation myocardial infarction. *Circ J.*
352 2015; 79: 1897-1899.
- 353 15. Mahase E. COVID-19: WHO declares pandemic because of "alarming levels" of
354 spread, severity, and inaction. *BMJ* 2020; 368: m1036.
- 355 16. Looi MK. COVID-19: Japan declares state of emergency as Tokyo cases soar. *BMJ*
356 2020; 369: m1447.
- 357 17. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth
358 Universal Definition of Myocardial Infarction (2018). *J Am Coll Cardiol.* 2018; 72:
359 2231-2264.
- 360 18. Kimura K, Kimura T, Ishihara M, Nakagawa Y, Nakao K, Miyauchi K, et al. JCS 2018
361 guideline on diagnosis and treatment of acute coronary syndrome. *Circ J.* 2019; 83:
362 1085-1196.
- 363 19. Tsukui T, Sakakura K, Taniguchi Y, Yamamoto K, Seguchi M, Wada H, et al.
364 Association between the door-to-balloon time and mid-term clinical outcomes in
365 patients with ST-segment elevation myocardial infarction. *Intern Med.* 2020; 59:
366 1597-1603.
- 367 20. Hochman JS, Buller CE, Sleeper LA, Boland J, Dzavik V, Sanborn TA, et al.

- 368 Cardiogenic shock complicating acute myocardial infarction--etiologies, management
369 and outcome: a report from the SHOCK Trial Registry. Should we emergently
370 revascularize Occluded Coronaries for cardiogenic shock? J Am Coll Cardiol.
371 2000; 36: 1063-1070.
- 372 21. Honda S, Asaumi Y, Yamane T, Nagai T, Miyagi T, Noguchi T, et al. Trends in the
373 clinical and pathological characteristics of cardiac rupture in patients with acute
374 myocardial infarction over 35 years. J Am Heart Assoc. 2014; 3: e000984.
- 375 22. Damluji AA, van Diepen S, Katz JN, Menon V, Tamis-Holland JE, Bakitas M, et al.
376 Mechanical complications of acute myocardial infarction: a scientific statement from
377 the American Heart Association. Circulation 2021; 144: e16-e35.
- 378 23. Novak M, Hlinomaz O, Groch L, Rezek M, Semenka J, Sikora J, et al. Ventricular
379 septal rupture - a critical condition as a complication of acute myocardial infarction. J
380 Crit Care Med (Targu Mures). 2015; 1: 162-166.
- 381 24. Osaka prefectural government-estimated population (monthly report). Available at:
382 <https://www.pref.osaka.lg.jp/toukei/jinkou/jinkou-xlslist.html>. Accessed March 27,
383 2022.
- 384 25. Japan medical analysis platform by the Japan Medical Association. Available at:
385 <https://jmap.jp/cities/detail/pref/27>. Accessed March 27, 2022.
- 386 26. Murphy SP, Ibrahim NE, Januzzi JL. Heart failure with reduced ejection fraction: a
387 review. JAMA 2020; 324: 488-504.
- 388 27. Packer M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, et al. Effect of
389 empagliflozin on the clinical stability of patients with heart failure and a reduced
390 ejection fraction: the EMPEROR-Reduced Trial. Circulation 2021; 143: 326-336.

- 391 28. Furui M, Sakurai Y, Kakii B, Asanuma M, Nishioka H, Yoshida T. Benefits and risks
392 of delayed surgery for ventricular septal rupture after acute myocardial infarction. *Int*
393 *Heart J* 2022; 63: 433-440.
- 394 29. Uriel N, Moravsky G, Blatt A, Tourovski A, Gabara Z, Inna Y, et al. Acute myocardial
395 infarction with spontaneous reperfusion: clinical characteristics and optimal timing for
396 revascularization. *Isr Med Assoc J.* 2007; 9: 243-246.
- 397 30. Li X, Li B, Gao J, Wang Y, Xue S, Jiang D, et al. Influence of angiographic
398 spontaneous coronary reperfusion on long-term prognosis in patients with ST-segment
399 elevation myocardial infarction. *Oncotarget* 2017; 8: 79767-79774.




Figure 1




Figure 2